Last --
Change Today 0.00 / 0.00%
Volume 0.0
All times are local (Market data is delayed by at least 15 minutes).

pfizer inc (PFZ) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
6.3B
EX-Date
11/5/14
P/E TM
--
Dividend
$1.04
Dividend Yield
--
Current Stock Chart for PFIZER INC (PFZ)

pfizer inc (PFZ) Details

Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines, and various consumer healthcare products. The company’s Primary Care segment offers prescription pharmaceutical products primarily prescribed by primary-care physicians for various therapeutic and disease areas comprising Alzheimer’s disease, cardiovascular, erectile dysfunction, genitourinary, major depressive disorder, pain, respiratory, and smoking cessation. Its Specialty Care and Oncology segment provides prescription pharmaceutical products for anti-infectives, endocrine disorders, hemophilia, inflammation, ophthalmology, pulmonary arterial hypertension, specialty neuroscience, and vaccines, as well as oncology and oncology-related illnesses. The company’s Established Products and Emerging Markets segment offers prescription pharmaceutical products that had lost patent protection or marketing exclusivity in certain countries and/or regions, as well as sold in emerging markets, including Asia, Latin America, the Middle East, Eastern Europe, Africa, Turkey, and Central Europe. Its Consumer Healthcare segment provides non-prescription products in a range of therapeutic categories, such as dietary supplements, pain management, respiratory, and personal care. The company also offers Lyrica, the Prevnar family of products, Enbrel, Celebrex, Lipitor, Viagra, Zyvox, Norvasc, Sutent, and the Premarin family of products; and consumer healthcare products under the Advil, Caltrate, Centrum, ChapStick, Emergen-C, Preparation H, and Robitussin brands. It serves wholesalers, distributors, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, and grocery and convenience stores. It has strategic alliance with CliniWorks (Israel) Ltd. to develop population health management platform with advanced analytics and patient care capabilities. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

77,700 Employees
Last Reported Date: 02/28/14
Founded in 1849

pfizer inc (PFZ) Top Compensated Officers

Chairman, Chief Executive Officer and Chairma...
Total Annual Compensation: $1.8M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $1.2M
President of Worldwide Research and Developme...
Total Annual Compensation: $1.1M
Group President of Global Innovative Pharma B...
Total Annual Compensation: $926.3K
Group President of Global Established Pharma ...
Total Annual Compensation: $810.1K
Compensation as of Fiscal Year 2013.

pfizer inc (PFZ) Key Developments

Pfizer Inc. Presents at BIO-Europe 2014, Nov-03-2014 04:15 PM

Pfizer Inc. Presents at BIO-Europe 2014, Nov-03-2014 04:15 PM. Venue: Portalhaus Messe Frankfurt, Strasse der Nationen, 60327 Frankfurt, Germany. Speakers: James Eshelby, Senior Director, Worldwide Business Development.

Pfizer Inc. Receives FDA Accelerated Approval for Trumenba(R) (Meningococcal Group B Vaccine) for Prevention of Invasive Meningococcal B Disease in Adolescents and Young Adults

Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of TRUMENBA(R) (meningococcal group B vaccine) for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B in individuals 10 through 25 years of age. Approval of TRUMENBA is based on demonstration of immune response, as measured by serum bactericidal activity against four serogroup B strains representative of prevalent strains in the United States. The effectiveness of TRUMENBA against diverse serogroup B strains has not been confirmed. As part of the accelerated approval process, Pfizer will complete its ongoing studies to confirm the effectiveness of TRUMENBA against diverse serogroup B strains. TRUMENBA was reviewed and approved under the FDA's Breakthrough Therapy designation and Priority Review programs. TRUMENBA is to be administered as a 3-dose series at months 0, 2 and 6 in the 10 through 25 year old age group.

Pfizer's PRISTIQ(R) (desvenlafaxine) Demonstrates Low Potential For Sexual Dysfunction in Adults with Major Depressive Disorder

Pfizer Inc. announced the publication of a clinical study in the Journal of Clinical Psychiatry showing comparable sexual function in adult patients diagnosed with major depressive disorder (MDD) treated daily with PRISTIQ Extended Release Tablets 50mg and 100mg doses versus placebo. Sexual dysfunction is often an issue for patients treated with antidepressants, and Pfizer conducted the study pursuant to a postmarketing requirement by the U.S. Food and Drug Administration (FDA). The primary end point of the study showed a statistically significant improvement among patients treated with PRISTIQ compared to placebo in symptoms of major depressive disorder as measured by the 17-item Hamilton Rating Scale for Depression (HAM-D17) total score over an 8-week period. The HAM-D17 is a validated assessment tool used to rate the severity of a patient's depressive symptoms. Sexual dysfunction was a secondary end point, and measured using the Arizona Sexual Experiences Scale (ASEX), a validated and reliable patient rated sexual function scale in the United States. In this Phase 4, multi-center, randomized, double- blind placebo-controlled study, a total of 924 patients, 18-years or older, with a baseline HAM-D17 score of >=20, were randomly assigned to PRISTIQ 50mg/day, PRISTIQ 100 mg/day or placebo in a 1:1:1 ratio over an 8-week period. The primary efficacy end point for the study was the change from baseline in HAM-D17 total score at week 8. In the primary efficacy analysis, a statistically greater change from baseline was observed in patients receiving PRISTIQ 50 mg and PRISTIQ 100mg compared with placebo. The most common treatment emergent adverse events observed were consistent with the known safety and tolerability profile of PRISTIQ. Sexual function was assessed using the ASEX Scale. The ASEX was selected over other validated scales because it is a brief but sensitive tool, less burdensome to patients than a more in-depth scale, and has been utilized in previous trials for desvenlafaxine and other antidepressant drugs. It measures five core elements of sexual function (sexual drive, arousal, penile erection/vaginal lubrication, ability to reach orgasm, and satisfaction from orgasm) rated on a six-point Likert scale. A Likert scale is a psychometric scale commonly utilized in research that employs questionnaires. A total score is calculated as the sum of all 5 individual item scores; negative numbers for change from baseline indicate improvement in sexual function. Incidence of sexual dysfunction was assessed using the ASEX data. In adult outpatients with MDD with baseline sexual activity and at least one post-baseline assessment, effects on ASEX total and item scores were comparable for the PRISTIQ 50 mg and PRISTIQ 100 mg groups and placebo. Rates of sexual dysfunction were comparable between each PRISTIQ dose and placebo at baseline (placebo, 52%; PRISTIQ 50 mg/d, 56%; PRISTIQ 100 mg/d, 54%) and at week 8 (placebo, 45%; PRISTIQ 50 mg/d, 49%; PRISTIQ 100 mg/d, 47%).

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PFZ:LN $0.00 USD 0.00

PFZ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
3M Co $158.31 USD +0.25
Bayer AG €119.40 EUR +1.58
Gilead Sciences Inc $100.30 USD -0.81
Merck & Co Inc $59.75 USD +0.41
Novartis AG SFr.92.05 CHF +0.50
View Industry Companies
 

Industry Analysis

PFZ

Industry Average

Valuation PFZ Industry Range
Price/Earnings 18.8x
Price/Sales 3.9x
Price/Book 2.5x
Price/Cash Flow 13.1x
TEV/Sales 2.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PFIZER INC, please visit www.pfizer.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.